Biotechnology

Sanofi's promising nerve disease drug fails in late-stage trials, leaving vulnerable patients in limbo and highlighting the brutal realities of medical innovation.

Mickey Mikitani shifts to Executive Chairman, installing a new CEO to navigate the high-stakes journey from visionary science to U.S. market reality.

Takeda seeks FDA approval for its gut-focused drug ENTYVIO in children, a major step toward a new era of treatment for the rising tide of pediatric IBD.

A novel TYK2 inhibitor that can enter the central nervous system has begun human trials, signaling a new frontier for treating diseases like MS and lupus.

New long-term data for masitinib shows a near doubling of 5-year survival for ALS patients, with many maintaining quality of life. Is this the turning point?

An industry award for TraceLink's OPUS platform signals a pivotal shift from passive automation to active AI 'agents' managing our most critical logistics.

A new partnership in regenerative medicine aims to capitalize on Florida's progressive laws. But does it signal a new era of healthspan or a risky medical frontier?

A new biologic, Nucala, gains Health Canada approval for a specific type of COPD, offering hope for patients and a new strategic frontier for GSK.

A survey reveals 75% of lab researchers prioritize peptide quality over price, a clear signal against the backdrop of a scientific reproducibility crisis.

Dana-Farber's historic $50M Yawkey grant funds more than a building; it fuels a new era of integrated research and patient-centric cancer treatment.

A market poised for 31% annual growth signals a new era for Alcohol-associated Liver Disease. As pharma chases a cure, a new class of drugs emerges.

A new partnership brings advanced embryo screening to the Pacific, promising healthier babies while igniting a global race and fierce ethical debates.

A new partnership between Biocartis and City of Hope seeks to transform pancreatic cancer outcomes by pairing breakthrough biomarkers with rapid diagnostic technology.

A Phase 1 trial launch is more than a milestone; it's a look at the future of pharma, where AI-driven speed and strategic global partnerships converge.

Matisse Pharmaceuticals' new sepsis drug just got a major boost from the FDA. But the real story is the invisible infrastructure—both biological and regulatory—it aims to master.

Phase 2a data shows a new drug not only stops bone-destroying cancer but heals the damage, with no adverse events. This is a strategic game-changer.

The genomics firm is unveiling two technologies aimed at slashing errors and automating key steps in DNA sequencing, a move that could reshape lab economics.

A $20M round for CELYSTRA Pharma isn't just a launch; it's a strategic maneuver to solve Canada's rare disease gap and redefine Québec's role in the market.

Enveric Biosciences heads to a key UBS investor day to pitch its non-hallucinogenic antidepressant, EB-003. Can it secure the capital needed to revolutionize CNS?

A new fellowship award spotlights how chronic stress rewrites our immune system, pointing to a future where we might reverse a key driver of aging.